menu search

Cidara therapeutics provides corporate update and reports third quarter 2023 financial results

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company focused on developing targeted therapi...

November 2, 2023, 8:15 pm

Karuna therapeutics: karxt could become a new standard of care in schizophrenia

Karuna Therapeutics, Inc. stock had >8x gain after my Buy rating before successful Phase 3 trial data for KarXT in treating schizophrenia. The stock h...

October 16, 2023, 2:41 pm

Syndax: biotech to watch with regulatory filings before end of 2023

Syndax Pharmaceuticals, Inc. reported positive results from its phase 1/2 trial using revumenib to treat relapsed/refractory leukemia patients. The tr...

October 13, 2023, 2:52 pm

Cidara therapeutics reports inducement grant under nasdaq listing rule 5635(c)(4)

SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® pl...

September 29, 2023, 8:51 pm

Candel therapeutics announces three abstracts accepted for poster presentations at sitc 2023 annual meeting

One clinical poster detailing initial overall survival and immunological biomarker data from the ongoing, randomized, open-label phase 2 clinical tria...

September 27, 2023, 1:40 pm

Chitogenx concludes enrolment for its us phase i/ii rotator cuff tear repair clinical trial

ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) said it has concluded the enrolment of 20 subjects in its US multi-site rotator cuff tear repair Phase I/II clin...

September 26, 2023, 8:11 am

Eagle pharmaceuticals to present cal02 trial in progress at the 2023 asm/escmid joint conference on drug development to meet the challenge of antimicrobial resistance

-- CAL02 is a unique therapeutic agent that is designed to work differently from antibiotics, aiming to disarm an infectious pathogen's virulence fact...

September 11, 2023, 6:50 am

Crinetics’ once-daily oral paltusotine achieved the primary and all secondary endpoints in the phase 3 pathfndr-1 study evaluating treatment of patients with acromegaly

83% of Participants on Paltusotine Maintained IGF-1 ≤1.0 xULN vs. 4% on placebo (p<0.0001) Mean IGF-1 Levels Were Maintained on Paltusotine vs. an I...

September 10, 2023, 2:00 pm

Cidara to present at the 25th annual h.c. wainwright global investment conference

SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company using its proprietary Cloudbreak® pl...

September 6, 2023, 8:05 pm

Cidara therapeutics provides update on status of ongoing cd388 influenza program

SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics de...

July 20, 2023, 9:00 pm

Kura oncology: targeted aml therapy continues to deliver

Kura Oncology, Inc. has additional updated results released from the KOMET-001 study, as part of an oral late-breaker presentation shown on June 11, 2...

July 12, 2023, 4:23 pm

Why moonlake immunotherapeutics stock skyrocketed this week

Earlier this week, MoonLake Immunotherapeutics announced positive mid-stage results for its hidradenitis suppurativa treatment. The therapy could beco...

June 29, 2023, 2:41 pm

Spectrum's rolvedon a differentiator in a $3b/yr market

Spectrum and Assertio's merger would lead to a diversified product portfolio and a combination of two unique marketing strategies. Spectrum's ROLVEDON...

June 22, 2023, 7:46 pm

Sarepta therapeutics: value proposition ahead of dmd gene therapy decision

Sarepta Therapeutics should earn ~$1bn from its Duchenne Muscular Dystrophy franchise in 2023 - although the company has made eye-watering losses in r...

June 22, 2023, 8:45 am

Fda expands pfizer's (pfe) talzenna label in prostate cancer

Following FDA's label-expansion approval, Pfizer's (PFE) Talzenna is the first PARP inhibitor approved in combination with existing ...

June 21, 2023, 3:34 pm

Eagle pharmaceuticals gets fda designations that will grant it extra exclusivity for bacterial pneumonia treatment

Eagle Pharmaceutics Inc. EGRX said Wednesday it has won Food and Drug Administration Qualified Infectious Disease Product (QDIP) and Fast-Track Design...

June 14, 2023, 7:05 am

Milestone scientific: sales could start to snowball

The shift to online sales in their dental business produced unexpectedly fast results with revenue and gross margin up sharply and more to come. Most ...

June 10, 2023, 11:52 pm

Why shares of rain oncology are plummeting today

Rain Oncology has milademetan in several trials. The oral therapy didn't show a big advantage over the current ...

May 22, 2023, 3:15 pm

Cidara therapeutics provides corporate update and reports first quarter 2023 financial results

SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics des...

May 11, 2023, 8:37 pm


Search within

Pages Search Results: